Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Saegis Pharmaceuticals
SGS742 is a GABA(B) receptor antagonist. It is an orally active drug and possesses neurochemical and psychopharmacologic features that suggest it could improve memory and cognition in humans. The primary objective of the SGS742 clinical trial will be to determine the effect of SGS742 on memory and cognition in individuals diagnosed with mild to moderate Alzheimer's disease. The duration of the study is 3 months with 5 clinic visits.
Age
55–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
55 to 90 years of age
Diagnosed with mild to moderate Alzheimer's disease
Willing caregiver
In general good health
You may not be if
Call 1-877-MY-MEMORY and ask to be referred to a study center located near you for entry criteria information.
